Keep Me Logged In
Valeant is having another rough day after Citron Research called the company's "Specialty Pharmacy" structure into question. Alex Arfaei, does not see fraud right now at the company, but explains why the firm downgraded the stock to market perform.
Got a confidential news tip? We want to hear from you.
Sign up for free newsletters and get more CNBC delivered to your inbox
© 2018 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Data also provided by